Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 30 Apr 24 424B5 Prospectus supplement for primary offering
- 29 Apr 24 424B5 Prospectus supplement for primary offering
- 30 Jan 23 424B5 Prospectus supplement for primary offering
- 30 Jan 23 424B5 Prospectus supplement for primary offering
- 26 Jan 23 424B5 Prospectus supplement for primary offering
- 8 Sep 22 EFFECT Notice of effectiveness
-
26 Aug 22 S-3 Shelf registration
WGS similar filings
Filing view
External links
Exhibit 23.2
Consent of Independent Auditors
We consent to the reference to our firm under the caption "Experts" in this Registration Statement (Form S-3) and related Prospectus of Sema4 Holdings Corp. and to the incorporation by reference therein of our report dated March 15, 2022, with respect to the combined carve out financial statements of GeneDx, Inc. and subsidiary, included in the Proxy Statement of Sema4 Holdings Corp. dated March 31, 2022, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP | |||||
Miami, Florida | |||||
August 26, 2022 |